Valuation: Jazz Pharmaceuticals plc

Market Cap 15.95B 14.01B 13.03B 11.95B 22.46B 1,536B 22.8B 155B 60.43B 755B 59.87B 58.58B 2,611B P/E 2026 *
18x
P/E 2027 * 16.3x
Enterprise Value 17.65B 15.5B 14.41B 13.23B 24.85B 1,699B 25.23B 171B 66.87B 835B 66.24B 64.81B 2,889B EV / Sales 2026 *
3.91x
EV / Sales 2027 * 3.3x
Free-Float
96.65%
Yield 2026 *
-
Yield 2027 * -
1 day-0.39%
1 week+2.56%
Current month+5.35%
1 month+10.37%
3 months+29.18%
6 months+52.61%
Current year+49.34%
1 week 242.11
Extreme 242.11
256.75
1 month 230.25
Extreme 230.25
256.75
Current year 156.95
Extreme 156.95
256.75
1 year 105
Extreme 105
256.75
3 years 95.49
Extreme 95.49
256.75
5 years 95.49
Extreme 95.49
256.75
10 years 86.88
Extreme 86.88
256.75
Manager TitleAgeSince
Chief Executive Officer 54 2025-08-10
Director of Finance/CFO 62 2024-02-29
Chief Tech/Sci/R&D Officer 54 2023-07-31
Director TitleAgeSince
Chairman 62 2003-02-28
Director/Board Member 65 2012-01-17
Director/Board Member 66 2009-12-31
Date Insider Type Main position Quantity % Market Cap.
7/1/26 Sell

Founder

-6,000 0.0096%
6/30/26 Tax

Executive/Senior Manager

-2,527 0.0040%
6/30/26 Tax

Chief Technology Officer

-3,764 0.0060%
Change 5-day change 1-year change 3-year change Capi.($)
-0.39%+2.56%+114.73%+94.15% 15.95B
+0.86%+1.43%+47.17%+163.68% 1,067B
+1.59%+4.09%+56.51%+52.50% 635B
+0.95%+1.91%+36.30%+82.78% 458B
+1.17%+8.53%+38.14%+32.13% 347B
+1.25%+4.48%+37.80%+41.73% 295B
+1.38%+3.78%+19.07%+20.07% 262B
+1.29%-0.90%-27.95%-38.92% 216B
+1.22%+2.66%+22.66%+59.87% 203B
-1.18%-3.70%+11.28%+67.52% 161B
Average +0.55%+1.45%+35.57%+57.55% 365.95B
Weighted average by Cap. +0.53%+1.95%+36.73%+79.43%

Financials

2026 *2027 *
Net sales 4.51B 3.96B 3.69B 3.38B 6.35B 434B 6.45B 43.76B 17.1B 214B 16.94B 16.57B 739B 4.84B 4.25B 3.95B 3.63B 6.82B 466B 6.92B 46.96B 18.35B 229B 18.17B 17.78B 792B
Net income 1.02B 898M 836M 767M 1.44B 98.51B 1.46B 9.92B 3.88B 48.43B 3.84B 3.76B 167B 1.07B 938M 872M 800M 1.5B 103B 1.53B 10.35B 4.05B 50.54B 4.01B 3.92B 175B
Net Debt 1.7B 1.49B 1.39B 1.27B 2.39B 164B 2.43B 16.47B 6.44B 80.4B 6.38B 6.24B 278B 15.43M 13.55M 12.6M 11.56M 21.73M 1.49B 22.06M 150M 58.46M 730M 57.92M 56.67M 2.53B
Logo Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
Employees
2,890
Date Price Change Volume
26-07-24 US$253.87 -0.39% 538,295
26-07-23 US$254.87 +1.78% 527,986
26-07-22 US$250.41 -1.50% 521,018
26-07-21 US$254.22 +4.42% 810,118
26-07-20 US$243.47 -1.64% 675,844
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
253.87USD
Average target price
266.90USD
Spread / Average Target
+5.13%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. JAZZ Stock